Skip to main content

Preoperative Labs

This page covers what is worth ordering versus what is reflex before reconstructive urologic and urogynecologic surgery. The high-yield message from the contemporary preoperative-testing literature is that routine "screening" labs in healthy ASA 1–2 patients undergoing low-risk procedures are low-value, drive false-positive workups, and delay care without changing outcomes.[1] This page is the labs-themselves companion to the broader Preoperative Assessment workflow.

When NOT to Order​

Routine CBC, metabolic and coagulation panels are often unnecessary for a healthy patient having a minor procedure. ASA class alone is insufficient: operation magnitude, comorbidities, medication use, prior results and anticipated blood loss determine testing. NICE NG45 recommends a CBC for major/complex surgery even in ASA 1–2 patients, while discouraging routine coagulation testing without an indication. Its adult framework should not be extrapolated automatically to pediatric hypospadias surgery.[1][9]

The contemporary urogynecologic evidence reinforces this directly. Samsel 2025 retrospectively reviewed 634 urogynecologic surgeries and found that 74% of women had preoperative labs performed, but clinically meaningful lab abnormalities were rare and did not change surgical management in any case. This single-center observational study supports selective testing; it does not establish that labs are unnecessary for every pelvic-floor operation or comorbidity.[4]

The framework below is organized around indications, not procedures.

Section 1 — Complete Blood Count (CBC)​

Indicated when:

  • Major reconstructive procedures with anticipated significant blood loss — radical cystectomy with urinary diversion, complex multistage urethroplasty with flap, abdominal sacrocolpopexy, gracilis-flap reconstruction for rectourethral fistula, vesicovaginal fistula repair after radiation
  • Patients on testosterone replacement therapy (TRT) — monitor for erythrocytosis. AUA advises withholding initiation when baseline Hct is >50% pending evaluation; on-treatment Hct ≥54% requires intervention, commonly dose adjustment and investigation. Follow the TRT monitoring plan, rather than automatically stopping every formulation[2]
  • Chronic hematuria — quantify anemia before reconstruction
  • Recent chemotherapy or known cytopenias — assess current blood counts and treatment recovery before a planned major operation; an oncology surveillance schedule does not determine preoperative testing
  • Known myelodysplasia, hemoglobinopathy, or chronic kidney disease

Usually omit a new CBC: low-blood-loss minor procedures in patients without an anemia/bleeding indication and with an appropriate recent assessment. Consider procedure magnitude and local anesthesia policy.[9]

Section 2 — Coagulation Studies (PT/INR, aPTT)​

Indicated when:

  • Personal or family history suggesting a bleeding disorder
  • Warfarin: INR when needed for the perioperative plan. Routine PT/aPTT cannot reliably exclude DOAC effect; when residual drug activity would change urgent management, use a drug-appropriate assay and expert interpretation
  • Liver disease or a suspected acquired coagulation defect, including clinically relevant vitamin K deficiency; a long-standing ileal conduit alone does not establish malabsorption
  • Unfractionated heparin when monitoring is needed; LMWH exposure does not by itself justify routine PT/aPTT
  • Severe systemic illness or sepsis

Skip when: Healthy ASA 1–2 patients with no bleeding history. The AAFP and ACP explicitly recommend against reflex PT/aPTT before noncardiac surgery in unselected patients.[1]

For perioperative anticoagulation timing and reversal strategy, see Antithrombotic Therapy and Anticoagulation Reversal.

Section 3 — Glucose / HbA1c​

HbA1c reflects preceding glycemia rather than an acute stress response, but altered red-cell survival, transfusion and some hemoglobin variants can make it misleading. Interpret it alongside current glucose and the clinical setting.[3]

Indicated when:

  • Known diabetes — confirm current control before elective major reconstruction
  • Diabetes case-finding when indicated by standard risk-based assessment or unexplained hyperglycemia; do not add HbA1c to every preoperative panel solely because surgery is planned
  • Refractory recurrent UTI, voiding dysfunction, or NLUTD presentations where occult diabetes is on the differential

Targets and timing. ADA 2026 recommends aiming for HbA1c <8% within 3 months before elective surgery with individualized risk–benefit assessment. It explicitly advises against postponing surgery on A1c or glucose-management indicator alone, because evidence that such delay improves outcomes is lacking. Current glucose, metabolic stability, infection, urgency and the operation's risks still matter. AHA/ACC considers checking a recent HbA1c reasonable in people with diabetes; the Endocrine Society's <8% preoperative target concerns patients with diabetes facing elective surgery, not every hospitalized patient.[5][6][7]

Glycosuria should be interpreted with plasma glucose, medications and renal physiology. It is expected during SGLT2-inhibitor use and does not by itself diagnose diabetes or poor control.

SGLT2 inhibitor caveat. SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin) should be withheld 3 days before elective surgery (4 days for ertugliflozin) to reduce the risk of perioperative euglycemic diabetic ketoacidosis.[6]

Skip when: ASA 1–2 patients with no diabetes risk factors undergoing low-risk procedures.

For broader diabetes optimization (insulin holds, SGLT2 inhibitor euglycemic DKA risk, perioperative insulin and glucose monitoring), see the Preoperative Assessment — Diabetes page.

Section 4 — BMP / CMP​

For routine general preoperative use (distinct from the lifelong diversion-specific surveillance covered at Renal Function & Metabolic Surveillance):

Indicated when:

  • Chronic kidney disease (any stage) — establishes baseline creatinine and electrolytes
  • On diuretics, ACE inhibitors, or ARBs — risk for hypokalemia, hyperkalemia, or pre-renal AKI
  • On medications with renal clearance (gabapentin, vancomycin, LMWH, methotrexate) requiring dose adjustment
  • Major surgery with anticipated significant fluid shifts (cystectomy, large flap reconstruction, prolonged operative time)
  • Adrenal insufficiency or chronic corticosteroid use (electrolyte and glucose baseline)

Skip when: Healthy ASA 1–2 patients undergoing outpatient or short-stay procedures, no medications requiring renal monitoring.[1]

Section 5 — Type and Screen / Type and Crossmatch​

Match the order to anticipated blood-loss volume, not to procedure category by reflex:

  • Type and screen: radical cystectomy with urinary diversion, complex urethroplasty with flap, large pedicled or free flap reconstruction (gracilis, VRAM, ALT), open sacrocolpopexy, complex fistula repair after radiation, augmentation cystoplasty, posterior urethroplasty for PFUI
  • Crossmatch / reserve units: when the expected transfusion requirement and local blood-ordering schedule justify it. Known antibodies warrant early blood-bank coordination; anemia or redo surgery alone does not specify a universal number of units
  • Skip: outpatient endoscopic procedures, simple slings, office-based procedures

Institutional MSBOS (maximum surgical blood ordering schedule) policies operationalize this — confirm local conventions.

When to Order vs. Skip — Quick Reference​

LabOrder WhenSkip When
CBCMajor reconstruction; chronic hematuria; on TRT; post-chemotherapy cystectomyCystoscopy; simple sling; minor low-blood-loss procedures without an anemia indication
PT/INR/aPTTBleeding history, warfarin monitoring or suspected coagulation defect; select the assay for the drugHealthy ASA 1–2 with no bleeding history
BMP/CMPCKD; on diuretics/ACE-I/ARB; major fluid shifts; chronic steroidsRoutine outpatient procedures in ASA 1–2
HbA1cKnown DM without a recent result; indicated diabetes case-findingASA 1–2 with no diabetes risk factors
Type & ScreenCystectomy/diversion; complex urethroplasty; large flap; sacrocolpopexyOutpatient endoscopic procedures
Type & CrossmatchExpected transfusion need and local blood-bank planRoutine cases without bleeding-risk features

Reconstruction-Specific Risk Factors That Change the Calculus​

Several patient cohorts seen disproportionately in reconstructive practice deserve more aggressive preoperative laboratory assessment than their ASA class would suggest:

  • Long-standing urinary diversion — chronic metabolic acidosis, hypokalemia, B12 deficiency (ileal segments), hyperchloremic acidosis (colonic segments). See Renal Function & Metabolic Surveillance
  • Spinal cord injury / NLUTD — autonomic dysreflexia risk, baseline renal function reflecting upper-tract status
  • Radiation history — anemia from chronic radiation cystitis bleeding, marrow effects from prior pelvic radiation
  • Testosterone-replacement and gender-affirming hormone therapy patients — Hct surveillance is mandatory[2]
  • Geriatric reconstructive patients — assess frailty, function, comorbidities and nutritional intake, then select labs. Albumin is influenced by inflammation and illness and is not a standalone nutrition diagnosis
  • Diabetes before urinary diversion — in Kim's observational cohort of 123 ileal-neobladder patients, diabetes was associated with acidosis at one year (adjusted OR 5.68); this is a cohort-specific risk estimate; see Renal Function & Metabolic Surveillance for the lifelong post-diversion lab framework[8]

See Also​

References​

1. Feely MA, Collins CS, Daniels PR, Kebede EB, Jatoi A, Mauck KF. "Preoperative Testing Before Noncardiac Surgery: Guidelines and Recommendations." Am Fam Physician. 2013;87(6):414–418. https://www.aafp.org/pubs/afp/issues/2013/0315/p414.html

2. AUA. Evaluation and Management of Testosterone Deficiency (2018; validity confirmed 2024). Guideline.

3. Sacks DB, Arnold M, Bakris GL, et al. "Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus." Diabetes Care. 2023;46(10):e151–e199. doi:10.2337/dci23-0036

4. Samsel T, Ashmore S, Shi J, Kenton K, Mueller M. "Surgical Management of Pelvic Floor Disorders and the Utility of Preoperative Labs." Int Urogynecol J. 2025. doi:10.1007/s00192-025-06307-7

5. American Diabetes Association Professional Practice Committee. "16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2026." Diabetes Care. 2026;49(Suppl_1):S339–S355. doi:10.2337/dc26-S016

6. Thompson A, Fleischmann KE, Smilowitz NR, et al. "2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery." J Am Coll Cardiol. 2024;84(19):1869–1969. doi:10.1016/j.jacc.2024.06.013

7. Korytkowski MT, Muniyappa R, Antinori-Lent K, et al. "Management of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline." J Clin Endocrinol Metab. 2022;107(8):2101–2128. doi:10.1210/clinem/dgac278

8. Kim KH, Yoon HS, Yoon H, et al. "Risk Factors for Developing Metabolic Acidosis after Radical Cystectomy and Ileal Neobladder." PLoS One. 2016;11(7):e0158220. doi:10.1371/journal.pone.0158220

9. NICE. Routine preoperative tests for elective surgery, NG45. Recommendations by surgery and ASA grade.